Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue…
Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024
Recover your password.
A password will be e-mailed to you.